BioMarin Pharmaceutical (NASDAQ:BMRN) Analyst Rating Consensus

BioMarin Pharmaceutical (NASDAQ:BMRN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.4 by 15 Brokerage Firm. 11 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 2 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. BMO Capital initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN). The shares have now been rated Outperform by the stock experts at the ratings house. The rating by the firm was issued on April 7, 2016.

BioMarin Pharmaceutical (NASDAQ:BMRN) should head towards $111.33 per share according to 15 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $99 per share. The higher price estimate target is at $150 according to the Analysts.

BioMarin Pharmaceutical (NASDAQ:BMRN) witnessed a decline in the market cap on Tuesday as its shares dropped 3.38% or 2.84 points. After the session commenced at $84.05, the stock reached the higher end at $84.05 while it hit a low of $80.545. With the volume soaring to 1,427,880 shares, the last trade was called at $81.22. The company has a 52-week high of $151.75. The company has a market cap of $13,184 million and there are 162,322,440 shares in outstanding. The 52-week low of the share price is $62.12.

Shares of BioMarin Pharmaceutical Inc. appreciated by 0.21% during the last five trading days but lost 6.05% on a 4-week basis. BioMarin Pharmaceutical Inc. has dropped 2.65% during the last 3-month period . Year-to-Date the stock performance stands at -22.47%.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *